Evidence map›Paper›PMID 39046639›Full record

ReviewCurrent HIV/AIDS reports2024

PrEP Method Switching: Will it Yield Greater Coverage of HIV Protection? Applying Lessons Learned from Family Planning to Guide Future Research in the Context of PrEP Choice.

Courtney McGuire, Margaret A Atieno, Theresa Hoke, Patriciah Jeckonia, Kevin K'orimba, Lara Lorenzetti, Kenneth Ngure, Marie Merci Niyibeshaho, Njambi Njuguna, Kristine Torjesen and 1 more

Abstract readReview
In one paragraph

Review in Current HIV/AIDS reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Courtney McGuireFHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA. cmcguire@fhi360.org.
Margaret A AtienoLVCT Health, Nairobi, Kenya.
Theresa HokeFHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA.
Patriciah JeckoniaLVCT Health, Nairobi, Kenya.
Kevin K'orimbaLVCT Health, Nairobi, Kenya.
Lara LorenzettiFHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA.
Kenneth NgureSchool of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Marie Merci NiyibeshahoLVCT Health, Nairobi, Kenya.
Njambi NjugunaFHI 360, Nairobi, Kenya.
Kristine TorjesenFHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA.
Virginia FonnerFHI 360, 359 Blackwell Street, Suite 200, Durham, NC, 27701, USA.

Funding

U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID) Cooperative Agreement 7200AA21CA00011
6 · The paper itself

Abstract

purpose of reviewDespite the growing availability of oral PrEP, coverage remains suboptimal. Through the introduction of additional PrEP methods, including vaginal rings and long-acting injectable formulations, health systems globally are on the cusp of offering PrEP methods that vary by route of administration, efficacy, and frequency of use. With PrEP choice, it will be important to explore PrEP use patterns to better understand how the ability to choose and switch products affects coverage and continuation. In this review, we draw parallels with family planning (FP) by summarizing how method choice and product switching affected contraceptive coverage globally, synthesize what is known about PrEP product switching, and outline evidence gaps to help guide future research on PrEP switching in the context of choice. RECENT

findingsDecades of research in FP has demonstrated that product switching is common and can lead to more satisfaction and increases in contraceptive use. While research on PrEP product switching is nascent, findings suggest switching is common, and that providing more than one PrEP option can increase coverage. Key evidence gaps include understanding product switching in the context of full versus constrained choice, switching in the context of temporary need, and developing interventions that promote product switching for those who could benefit. Providing choice and allowing people to start, stop, and switch products according to their needs and desires is a core component of a rights-based approach to HIV prevention. More research is needed to better understand what drives use patterns, including switching, and how to leverage choice to improve coverage. Standard definitions -some of which have been proposed in this review-are needed to inform comparable measurement. Finally, there is a need to holistically frame PrEP use to acknowledge changes in need over the life course, thus making method switching a standard part of HIV prevention.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisFamily Planning ServicesFemaleHumansAnti-HIV AgentsHIV PreventionLife courseMethod ChoiceMethod DiscontinuationMethod SwitchingPre-exposure prophylaxis

Identifiers

PMID39046639
PMCPMC11377463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.